CRDF: Cardiff Oncology, Inc.
About
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Current Value
$2.501 Year Return
Current Value
$2.501 Year Return
Key Details
Market Cap
$127.83M
P/E Ratio
-2.63
1Y Stock Return
110.08%
1Y Revenue Growth
49.78%
Dividend Yield
0.00%
Price to Book
2.5
Strategies that include CRDF
Stock's related to CRDF
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACIC | -22.08% | $642.09M | +62.64% | 0.00% |
| FLG | -21.52% | $4.47B | -60.64% | 0.64% |
| VYX | -21.50% | $2.13B | -9.51% | 0.00% |
| CBOE | -19.99% | $22.09B | +17.17% | 1.08% |
| JAKK | -19.48% | $304.87M | -9.05% | 0.00% |
| TSLX | -16.67% | - | - | 9.25% |
| TSN | -14.65% | $22.25B | +32.83% | 3.06% |
| LUNA | -14.00% | $55.69M | -73.11% | 0.00% |
| XEL | -13.62% | $42.49B | +18.12% | 3.02% |
| TTEC | -13.43% | $229.58M | -73.96% | 1.25% |
| GAN | -12.60% | $82.94M | +20.53% | 0.00% |
| PULM | -10.70% | $22.32M | +230.27% | 0.00% |
| THG | -9.65% | $5.86B | +34.60% | 2.10% |
| CNA | -9.40% | $13.33B | +23.85% | 3.57% |
| EVRI | -9.28% | $1.15B | +22.51% | 0.00% |
| XGN | -9.26% | $69.14M | +151.28% | 0.00% |
| UPLD | -9.22% | $90.01M | -26.79% | 0.00% |
| IMRN | -9.20% | $10.94M | +6.06% | 0.00% |
| UNH | -9.19% | $549.86B | +9.88% | 1.34% |
| PX | -9.16% | $1.52B | +40.35% | 0.99% |
ETF's related to CRDF
News
Yahoo
- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 12,144,813 with an expected expiration date of no earlier th
Yahoo
Cardiff Oncology ( NASDAQ:CRDF ) Third Quarter 2024 Results Key Financial Results Net loss: US$11.9m (loss widened by...
Yahoo
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition
Finnhub
SAN DIEGO — SAN DIEGO — Cardiff Oncology, Inc. on Thursday reported a loss of $11.9 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 25...
SeekingAlpha
Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder dilution. Find out why CRDF stock is a Buy.
Yahoo
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis resulted in a 7.7-fold higher clinical benefit in bev-naïve patients with an ORR of 77% compared to 10% in bev-exposed patients - - Results from this trial, along with translational studies, supported the transition of clinical development of onvansertib to first-line RAS-mutant mCRC - - Initial readout f
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.